Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 5/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | BCL3 | P20749 | 5/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | JAK1 | P23458 | 1/20 | 0.41 |
| ▸ | TYK2 | P29597 | 1/20 | 0.41 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29593837 | 0.87 | MAPK14 (0.72) | MAPK14MAPK11 | |
| SCHEMBL4380074 | 0.87 | MAPK14 (0.72) | MAPK14MAPK11 | |
| SCHEMBL3526613 | 0.79 | MAPK14 (0.58) | MAPK14MAPK11 | |
| SCHEMBL3527648 | 0.79 | MAPK14 (0.52) | MAPK14MAPK11 | |
| SCHEMBL3523509 | 0.78 | MAPK14 (0.50) | MAPK14 | |
| SCHEMBL3522660 | 0.77 | MAPK14 (0.52) | MAPK14 | |
| SCHEMBL6471292 | 0.76 | BCL3 (0.49) | MAPK14BCL3KMT2ASMN1; SMN2JAK1 | |
| SCHEMBL3523043 | 0.76 | MAPK14 (0.64) | MAPK14MAPK11 | |
| SCHEMBL3522325 | 0.75 | MAPK14 (0.56) | MAPK14 | |
| SCHEMBL3526045 | 0.75 | MAPK14 (0.53) | MAPK14MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7183287-B2 | Substituted pyrimidinones | PHARMACIA CORPORATION (US) | 2007-02-27 | — | — | US | disclosed |
| US-20040242608-A1 | Substituted pyrimidinones | PHARMACIA LLC | 2004-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242608-A1 | Substituted pyrimidinones | MAPK1, MAPK7, MAP3K8 | MAPK14 29/4885TSHR 2512/4885BCL3 2661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.